The C-BRIDGE Study: China Bronchiectasis Research Involving Databases, Genomics, and Endotyping

Launched by SHANGHAI PULMONARY HOSPITAL, SHANGHAI, CHINA · Mar 23, 2025

Keywords

ClinConnect Summary

The C-BRIDGE Study is a clinical trial focused on understanding bronchiectasis, a lung condition that causes breathing difficulties due to damaged airways. This study aims to identify different types of bronchiectasis in Chinese patients, especially how their specific characteristics can help doctors predict how the disease will progress and how patients will respond to treatments. By looking at factors like genetics and inflammation, researchers hope to develop tailored treatment plans that can improve care for bronchiectasis patients not just in China, but around the world.

To participate in the study, individuals must be aged 18 or older and have a confirmed diagnosis of bronchiectasis shown by a CT scan, along with symptoms like a persistent cough or frequent lung infections. Participants should be stable, meaning they haven’t needed certain medications for lung flare-ups in the last month. The study will involve assessments over time to gather important information about bronchiectasis and help create more effective, personalized treatment strategies based on the findings.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • A prior CT scan confirming bronchiectasis, accompanied by a compatible clinical syndrome including cough, sputum production, and/or recurrent respiratory tract infections.
• • At the screening visit, participants must have been clinically stable for 4 weeks, defined as no antibiotic or corticosteroid treatment for a pulmonary exacerbation in the preceding 4 weeks.
• Exclusion Criteria:
• • Inability to provide informed consent
• • Age under 18 years
• • Patients with active tuberculosis
• • Use of antibiotics or corticosteroids for a pulmonary exacerbation within the past 4 weeks